Literature DB >> 9668451

A PCR-based field evaluation of Theileria infections in cattle and ticks in Kenya.

D Watt1, H Kiara, O A Sparagano.   

Abstract

Theileria parva is a hemoprotozoan parasite responsible for causing East Coast fever in east and central Africa. The vaccine currently available is an "infection and treatment" procedure which involves the injection of live sporozoites followed by drug therapy to prevent clinical illness. Before introducing potentially new strains of parasite into an area, however, it is crucial to check the disease situation in the field first. We looked at three different areas in Kenya: Limuru in which many cattle have already been vaccinated and Kitale and Kakamega which so far have not been vaccinated. Genus and species specific primers were used to test for the presence of Theileria species in blood and tick samples collected from the three areas. Limuru showed a cattle and tick infection prevalence of 27% and 2.3% respectively with T. parva. Kitale showed a cattle and tick infection prevalence of 100% and 14.2% respectively while Kakamega showed 100% and 0% respectively. Reasons for variations between areas involving vaccination status and epidemiological data are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9668451     DOI: 10.1111/j.1749-6632.1998.tb11035.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  A nested PCR assay exhibits enhanced sensitivity for detection of Theileria parva infections in bovine blood samples from carrier animals.

Authors:  David O Odongo; Jack D Sunter; Henry K Kiara; Robert A Skilton; Richard P Bishop
Journal:  Parasitol Res       Date:  2009-11-10       Impact factor: 2.289

2.  Molecular identification of Ehrlichia, Anaplasma, Babesia and Theileria in African elephants and their ticks.

Authors:  Edward King'ori; Vincent Obanda; Patrick I Chiyo; Ramon C Soriguer; Patrocinio Morrondo; Samer Angelone
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.